{"id":"https://openalex.org/W2314978377","doi":"https://doi.org/10.1055/s-2006-946559","title":"Adh\u00e4renz mit t\u00e4glichen und w\u00f6chentlichen oralen Bisphosphonaten in der Osteoporosetherapie","display_name":"Adh\u00e4renz mit t\u00e4glichen und w\u00f6chentlichen oralen Bisphosphonaten in der Osteoporosetherapie","alternate_titles":[],"publication_year":2006,"publication_date":"2006-06-01","ids":{"openalex":"https://openalex.org/W2314978377","doi":"https://doi.org/10.1055/s-2006-946559","mag":"2314978377","pmid":"https://pubmed.ncbi.nlm.nih.gov/16755420"},"language":"de","primary_location":{"id":"doi:10.1055/s-2006-946559","doi":"https://doi.org/10.1055/s-2006-946559","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-2006-946559","pdf_url":null,"source":{"id":"https://openalex.org/S38943393","display_name":"DMW - Deutsche Medizinische Wochenschrift","issn_l":"0012-0472","issn":["0012-0472","1439-4413"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"DMW - Deutsche Medizinische Wochenschrift","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2314978377"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052980195","display_name":"Reiner Bartl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018771216","display_name":"LMU Klinikum","ror":"https://ror.org/02jet3w32","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]},{"id":"https://openalex.org/I8204097","display_name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","ror":"https://ror.org/05591te55","country_code":"DE","type":"education","lineage":["https://openalex.org/I8204097"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"R Bartl","raw_affiliation_strings":["Bayerisches Osteoporosezentrum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t M\u00fcnchen, Grosshadern, M\u00fcnchen","Bayerisches Osteoporosezentrum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t M\u00fcnchen, Gro\u00dfhadern, M\u00fcnchen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayerisches Osteoporosezentrum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t M\u00fcnchen, Grosshadern, M\u00fcnchen","institution_ids":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]},{"raw_affiliation_string":"Bayerisches Osteoporosezentrum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t M\u00fcnchen, Gro\u00dfhadern, M\u00fcnchen","institution_ids":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024698434","display_name":"Siegfried G\u00f6tte","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S G\u00f6tte","raw_affiliation_strings":["Berufsverband der Fach\u00e4rzte f\u00fcr Orthop\u00e4die, Berlin"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Berufsverband der Fach\u00e4rzte f\u00fcr Orthop\u00e4die, Berlin","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103149255","display_name":"Peyman Hadji","orcid":"https://orcid.org/0000-0001-5228-6387","observed_orcids":["https://orcid.org/0000-0001-5228-6387"]},"institutions":[{"id":"https://openalex.org/I161103922","display_name":"Philipps University of Marburg","ror":"https://ror.org/01rdrb571","country_code":"DE","type":"education","lineage":["https://openalex.org/I161103922"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"P Hadji","raw_affiliation_strings":["Klinik f\u00fcr Gyn\u00e4kologie, gyn. Endokrinologie und Onkologie, Philipps-Universit\u00e4t Marburg, Marburg"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Klinik f\u00fcr Gyn\u00e4kologie, gyn. Endokrinologie und Onkologie, Philipps-Universit\u00e4t Marburg, Marburg","institution_ids":["https://openalex.org/I161103922"]}]},{"author_position":"last","author":{"id":null,"display_name":"T Hammerschmidt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Hammerschmidt","raw_affiliation_strings":["Corporate Affairs & Business Support, GlaxoSmithKline GmbH & Co. KG, M\u00fcnchen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Corporate Affairs & Business Support, GlaxoSmithKline GmbH & Co. KG, M\u00fcnchen","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.4603,"has_fulltext":false,"cited_by_count":43,"citation_normalized_percentile":{"value":0.93607641,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"131","issue":"22","first_page":"1257","last_page":"1262"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10071","display_name":"Bone health and osteoporosis research","score":0.0272000003606081,"subfield":{"id":"https://openalex.org/subfields/2732","display_name":"Orthopedics and Sports Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osteoporosis","display_name":"osteoporosis","score":0.7310000061988831},{"id":"https://openalex.org/keywords/bisphosphonates","display_name":"bisphosphonates","score":0.9210000038146973},{"id":"https://openalex.org/keywords/alendronate","display_name":"alendronate","score":0.996999979019165},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8199999928474426},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7580000162124634},{"id":"https://openalex.org/keywords/medication-possession-ratio","display_name":"medication possession ratio","score":0.6940000057220459},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.828000009059906},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.6380000114440918},{"id":"https://openalex.org/keywords/prescription-claims-data","display_name":"prescription claims data","score":0.5889999866485596}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5576432347297668},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.4767954349517822},{"id":"https://openalex.org/C2781318095","wikidata":"https://www.wikidata.org/wiki/Q33127638","display_name":"General practice","level":2,"score":0.46375539898872375},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.2647832930088043}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004164","descriptor_name":"Diphosphonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004164","descriptor_name":"Diphosphonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010342","descriptor_name":"Patient Acceptance of Health Care","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D010352","descriptor_name":"Patient Dropouts","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015663","descriptor_name":"Osteoporosis, Postmenopausal","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015663","descriptor_name":"Osteoporosis, Postmenopausal","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019386","descriptor_name":"Alendronate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D019386","descriptor_name":"Alendronate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1055/s-2006-946559","doi":"https://doi.org/10.1055/s-2006-946559","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-2006-946559","pdf_url":null,"source":{"id":"https://openalex.org/S38943393","display_name":"DMW - Deutsche Medizinische Wochenschrift","issn_l":"0012-0472","issn":["0012-0472","1439-4413"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-20","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"DMW - Deutsche Medizinische Wochenschrift","raw_type":"journal-article"},{"id":"pmid:16755420","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16755420","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Deutsche medizinische Wochenschrift (1946)","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2074724534","https://openalex.org/W1998033364","https://openalex.org/W2060406636","https://openalex.org/W2024717495","https://openalex.org/W1985327136","https://openalex.org/W2104922575","https://openalex.org/W2113877852","https://openalex.org/W2313102627","https://openalex.org/W1991705854","https://openalex.org/W2034835478"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVE:":[2],"Bisphosphonates":[3],"provide":[4],"efficacious":[5],"treatment":[6,93,175,228,266],"for":[7,64,103,265],"osteoporosis.":[8,43],"However,":[9],"side":[10],"effects":[11],"often":[12],"lead":[13],"to":[14,268],"patients":[15,41,55,89,150,162,199,214,226,235],"discontinuing":[16,234],"this":[17],"treatment.":[18],"This":[19],"study":[20],"analyses":[21],"differences":[22],"in":[23,251],"adherence":[24],"(including":[25],"acceptance,":[26,257],"persistence":[27,258],"and":[28,33,59,259],"compliance)":[29],"between":[30],"daily":[31,180],"(ALD-D)":[32,148,160,211],"weekly":[34],"(ALD-W)":[35,145,157,190,202,208],"administration":[36,181],"of":[37,48,52,88,117,138,149,161,170,213,225,233,253],"alendronate":[38],"among":[39,197],"German":[40],"with":[42,125,179,229],"METHODS:":[44],"Prescription":[45],"claims":[46],"data":[47],"two":[49],"random":[50],"groups":[51],"subjects":[53],"(144":[54],"each)":[56],"taking":[57],"ALD-D":[58],"ALD-W,":[60],"respectively,":[61],"were":[62],"observed":[63],"12":[65],"months":[66],"after":[67,94,153],"starting":[68],"the":[69,76,79,91,95,109,115,121,126,136,166,174],"given":[70],"prescription.":[71,155,241],"Termination":[72],"was":[73,98,106,123,176,187,200,249],"defined":[74],"as":[75,100],"moment":[77],"when":[78],"last":[80],"prescription":[81,97],"had":[82],"been":[83],"used":[84,99],"up.":[85],"The":[86,168],"percentage":[87,116],"continuing":[90],"drug":[92],"first":[96,240],"a":[101,216,231,263],"measure":[102],"acceptance.":[104],"Compliance":[105],"measured":[107],"by":[108,245],"medication":[110],"possession":[111],"ratio":[112],"(MPR),":[113],"namely":[114],"days":[118,189,193],"on":[119],"which":[120],"patient":[122],"supplied":[124],"medication.":[127],"An":[128],"MPR":[129],">":[130],"80%":[131],"is":[132,140,262],"therapeutically":[133,217],"relevant":[134,218],"because":[135],"risk":[137],"fractures":[139],"significantly":[141,177],"reduced.":[142],"RESULTS:":[143],"31.3%":[144],"vs.":[146,158,191,203,209],"45.8%":[147],"discontinued":[151,163,173,227],"therapy":[152,164],"one":[154],"53.5%":[156],"72.2%":[159],"throughout":[165],"year.":[167],"proportion":[169,224],"those":[171],"who":[172],"higher":[178],"(p=0.0035).":[182],"Mean":[183,195],"time":[184],"until":[185],"discontinuation":[186],"220":[188],"169":[192],"(ALD-D).":[194],"compliance":[196,219],"any":[198],"51.7%":[201],"37.7%":[204],"(ALD-D);":[205],"Only":[206],"30.6%":[207],"19.2%":[210],"(p=0,0295)":[212],"reached":[215],"level.":[220],"CONCLUSIONS:":[221],"A":[222],"large":[223],"bisphosphonates,":[230],"majority":[232],"not":[236],"even":[237],"refilling":[238],"their":[239],"Adherence,":[242],"although":[243],"enhanced":[244],"less":[246],"frequent":[247],"dosing,":[248],"suboptimal":[250],"all":[252],"its":[254],"aspects,":[255],"i.e.":[256],"compliance.":[260],"There":[261],"need":[264],"strategies":[267],"increase":[269],"adherence.":[270]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2314978377","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
